Home Industries Market Insights About Us Publisher Contact us

Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity

Published Date : 30-Jul-2021

Report Id : HNY198726

Pages : 110

Region: APAC

Asia Pacific multiple sclerosis drugs market will grow by 6.5% annually with a total addressable market cap of $33.56 billion over 2120-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
Highlighted with 35 tables and 54 figures, this 110-page report “Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country.
Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
o Other Immunomodulators
• Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta
o Other Immunosuppressants
Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Monoclonal Antibodies
• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Corticosteroids
• Adrenocorticotropic Hormone
• Other Drug Classes
Based on Drug Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Large-molecule Drugs
• Small-molecule Drugs
Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Oral Administration
• Parenteral Administration
Based on MS Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)
Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbvie, Inc.
Acorda Therapeutics Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KgaA
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Asia Pacific Market by Drug Type 41
3.1 Market Overview by Drug Type 41
3.2 Immunomodulators 43
3.3 Immunosuppressants 45
4 Segmentation of Asia Pacific Market by Drug Class 47
4.1 Market Overview by Drug Class 47
4.2 Monoclonal Antibodies 49
4.3 Interferon Beta 50
4.4 Sphingosine 1 Phosphate Receptor Modulators 51
4.5 Mixed Polymers 52
4.6 NF-κB Inhibitor 53
4.7 Pyrimidine Synthesis Inhibitor 54
4.8 Corticosteroids 55
4.9 Adrenocorticotropic Hormone 56
4.10 Other Drug Classes 57
5 Segmentation of Asia Pacific Market by Drug Category 58
5.1 Market Overview by Drug Category 58
5.2 Large-molecule Drugs 60
5.3 Small-molecule Drugs 61
6 Segmentation of Asia Pacific Market by Route of Administration 62
6.1 Market Overview by Route of Administration 62
6.2 Oral Administration 64
6.3 Parenteral Administration 65
7 Segmentation of Asia Pacific Market by MS Type 66
7.1 Market Overview by MS Type 66
7.2 Relapsing-remitting MS (RRMS) 68
7.3 Primary-progressive MS (PPMS) 69
7.4 Secondary-progressive MS (SPMS) 70
7.5 Progressive-relapsing MS (PRMS) 71
8 Segmentation of Asia Pacific Market by Distribution Channel 72
8.1 Market Overview by Distribution Channel 72
8.2 Hospital Pharmacies 74
8.3 Retail Pharmacies 75
8.4 Online Pharmacies 76
9 Asia-Pacific Market 2020-2027 by Country 77
9.1 Overview of Asia-Pacific Market 77
9.2 China 80
9.3 Japan 82
9.4 India 85
9.5 Australia 87
9.6 South Korea 89
9.7 Rest of APAC Region 91
10 Competitive Landscape 93
10.1 Overview of Key Vendors 93
10.2 New Product Launch, Partnership, Investment, and M&A 96
10.3 Company Profiles 97
Abbvie, Inc. 97
Acorda Therapeutics Inc. 99
Bayer AG 100
Biogen Inc. 101
Bristol-Myers Squibb Company 102
F. Hoffmann-La Roche Ltd. 103
Merck KgaA 104
Mylan NV 105
Novartis AG 106
Pfizer Inc. 107
Sanofi SA 108
Teva Pharmaceutical Industries Ltd. 109
RELATED REPORTS 110
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 16
Figure 4. Asia Pacific Multiple Sclerosis Drugs Market, 2017-2027, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Multiple Sclerosis Drugs Market 24
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Multiple Sclerosis Drugs Market 29
Figure 10. Investment Opportunity Analysis 34
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Multiple Sclerosis Drugs Market 37
Figure 12. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Type, 2020-2027, % of Revenue 41
Figure 13. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 42
Figure 14. Asia Pacific Multiple Sclerosis Drugs Market: Immunomodulators, 2017-2027, $ mn 43
Figure 15. Asia Pacific Multiple Sclerosis Drugs Market: Immunosuppressants, 2017-2027, $ mn 45
Figure 16. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Class, 2020-2027, % of Revenue 48
Figure 17. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Class, Value ($ mn) and Share (%) 48
Figure 18. Asia Pacific Multiple Sclerosis Drugs Market: Monoclonal Antibodies, 2017-2027, $ mn 49
Figure 19. Asia Pacific Multiple Sclerosis Drugs Market: Interferon Beta, 2017-2027, $ mn 50
Figure 20. Asia Pacific Multiple Sclerosis Drugs Market: Sphingosine 1 Phosphate Receptor Modulators, 2017-2027, $ mn 51
Figure 21. Asia Pacific Multiple Sclerosis Drugs Market: Mixed Polymers, 2017-2027, $ mn 52
Figure 22. Asia Pacific Multiple Sclerosis Drugs Market: NF-κB Inhibitor, 2017-2027, $ mn 53
Figure 23. Asia Pacific Multiple Sclerosis Drugs Market: Pyrimidine Synthesis Inhibitor, 2017-2027, $ mn 54
Figure 24. Asia Pacific Multiple Sclerosis Drugs Market: Corticosteroids, 2017-2027, $ mn 55
Figure 25. Asia Pacific Multiple Sclerosis Drugs Market: Adrenocorticotropic Hormone, 2017-2027, $ mn 56
Figure 26. Asia Pacific Multiple Sclerosis Drugs Market: Other Drug Classes, 2017-2027, $ mn 57
Figure 27. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Drug Category, 2020-2027, % of Revenue 58
Figure 28. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Category, Value ($ mn) and Share (%) 59
Figure 29. Asia Pacific Multiple Sclerosis Drugs Market: Large-molecule Drugs, 2017-2027, $ mn 60
Figure 30. Asia Pacific Multiple Sclerosis Drugs Market: Small-molecule Drugs, 2017-2027, $ mn 61
Figure 31. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Route of Administration, 2020-2027, % of Revenue 62
Figure 32. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Route of Administration, Value ($ mn) and Share (%) 63
Figure 33. Asia Pacific Multiple Sclerosis Drugs Market: Oral Administration, 2017-2027, $ mn 64
Figure 34. Asia Pacific Multiple Sclerosis Drugs Market: Parenteral Administration, 2017-2027, $ mn 65
Figure 35. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by MS Type, 2020-2027, % of Revenue 66
Figure 36. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by MS Type, Value ($ mn) and Share (%) 67
Figure 37. Asia Pacific Multiple Sclerosis Drugs Market: Relapsing-remitting MS (RRMS), 2017-2027, $ mn 68
Figure 38. Asia Pacific Multiple Sclerosis Drugs Market: Primary-progressive MS (PPMS), 2017-2027, $ mn 69
Figure 39. Asia Pacific Multiple Sclerosis Drugs Market: Secondary-progressive MS (SPMS), 2017-2027, $ mn 70
Figure 40. Asia Pacific Multiple Sclerosis Drugs Market: Progressive-relapsing MS (PRMS), 2017-2027, $ mn 71
Figure 41. Breakdown of Asia Pacific Multiple Sclerosis Drugs Market by Distribution Channel, 2020-2027, % of Revenue 72
Figure 42. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 73
Figure 43. Asia Pacific Multiple Sclerosis Drugs Market: Hospital Pharmacies, 2017-2027, $ mn 74
Figure 44. Asia Pacific Multiple Sclerosis Drugs Market: Retail Pharmacies, 2017-2027, $ mn 75
Figure 45. Asia Pacific Multiple Sclerosis Drugs Market: Online Pharmacies, 2017-2027, $ mn 76
Figure 46. Breakdown of APAC Multiple Sclerosis Drugs Market by Country, 2020 and 2027, % of Revenue 78
Figure 47. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 79
Figure 48. Multiple Sclerosis Drugs Market in China, 2017-2027, $ mn 80
Figure 49. Multiple Sclerosis Drugs Market in Japan, 2017-2027, $ mn 83
Figure 50. Multiple Sclerosis Drugs Market in India, 2017-2027, $ mn 85
Figure 51. Multiple Sclerosis Drugs Market in Australia, 2017-2027, $ mn 87
Figure 52. Multiple Sclerosis Drugs Market in South Korea, 2017-2027, $ mn 89
Figure 53. Multiple Sclerosis Drugs Market in Rest of APAC, 2017-2027, $ mn 91
Figure 54. Growth Stage of Asia Pacific Multiple Sclerosis Drugs Industry over the Forecast Period 93

Request For Discount

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any), so we can get back to you with a solution

Buy Now

Single User

US$ 2900

Multi User

US$ 4000

Corporate User

US$ 5100

Related Reports

Asia Pacific Multiple Sclerosis Drugs Market 2020-...

RD Code : HNY198726